Terns Pharmaceuticals Reports Positive Phase 1 Results of TERN-601 for Obesity Treatment

Monday, 9 September 2024, 06:06

Terns Pharmaceuticals has announced positive Phase 1 clinical trial results for TERN-601, a once-daily oral GLP-1R agonist for obesity treatment. The study demonstrated mean weight loss of 5.5% over 28 days, with a 4.9% placebo-adjusted result. TERN-601 was well tolerated and showcased no treatment-related dose limiting factors.
LivaRava_Medicine_Default.png
Terns Pharmaceuticals Reports Positive Phase 1 Results of TERN-601 for Obesity Treatment

Overview of TERN-601 Clinical Trials

Terns Pharmaceuticals has successfully conducted a Phase 1 clinical trial evaluating TERN-601, a once-daily oral GLP-1R agonist tailored for the treatment of obesity. The trial reported remarkable results, indicating statistical significance in mean weight loss.

Results and Efficacy

The results revealed an impressive mean weight loss of 5.5% over the span of 28 days, adjusted for a placebo which showcased a 4.9% difference. This positions TERN-601 as a promising candidate in the obesity therapeutic landscape.

Tolerability and Safety

  • Well tolerated: Patients reported minimal side effects.
  • No treatment-related dose limiting: Factors were identified that could skew outcomes.

These findings highlight the potential of TERN-601 not just as a weight management solution but as a new frontier in obesity treatment therapies.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe